Seeking Alpha

Joe2922

Joe2922
Send Message
View as an RSS Feed
View Joe2922's Comments BY TICKER:
Latest  |  Highest rated
  • Alibaba confirms plans to list in the U.S. [View news story]
    Funny typo!: Alibaba hasn't decided which exchange it will lost on, nor on a date.
    Mar 16 07:29 AM | 3 Likes Like |Link to Comment
  • Navidea Biopharmaceuticals: 4 Reasons To Buy This $2 Lottery Ticket [View article]
    What he said was reorder rates are 98%. The ones who have not reordered yet have not had a need for it yet. Better to read the filings and the conference call notes than SA articles.
    Mar 11 02:11 PM | Likes Like |Link to Comment
  • Navidea Biopharmaceuticals: 4 Reasons To Buy This $2 Lottery Ticket [View article]
    Top line Phase III data from nav4694 coming early third quarter, and P2b this year also.
    5001 is also in final testing stage
    Mar 10 03:40 PM | Likes Like |Link to Comment
  • Navidea Biopharmaceuticals: 4 Reasons To Buy This $2 Lottery Ticket [View article]
    It was 20 cents in Jan., 2008 -- stocks do wild & crazy things, don't blame them for your losses, look in your mirror to see who's at fault. Stocks always overshoot both ways!
    Mar 10 02:24 PM | 1 Like Like |Link to Comment
  • Navidea Biopharmaceuticals: 4 Reasons To Buy This $2 Lottery Ticket [View article]
    Look forward, not backward - stocks are forecasting mechanisms. If/When market pays for MCI diagnoses, this one will soar higher. I believe it's also a takeover candidate within 1 or 2 yrs.
    Mar 10 12:39 PM | 4 Likes Like |Link to Comment
  • Gold: Has The Bull Started To Run Again? [View article]
    I found it for all of you, if you have any interest in gold or gold stocks, you owe it to yourself to read this brilliant article about it, the best one I've read in my 31 years of investing and trading:
    http://bit.ly/1hiusAV
    Feb 14 08:22 AM | Likes Like |Link to Comment
  • Gold: Has The Bull Started To Run Again? [View article]
    Without what many believe it to be, shiny, etc., it would sell for around $8 an ounce.
    Best article I ever read about it came from Mauldineconomics.com outside the box but I just bought a new computer and can't find it now. It's at that website.
    Sorry I can't link it for you, I won't return to discuss this more, I have my beliefs and trade what others think is true sometimes. I don't force the market to believe what I do! I just want to make money.
    Feb 13 08:41 PM | Likes Like |Link to Comment
  • Gold: Has The Bull Started To Run Again? [View article]
    Leveraged ETFs decay and slip badly, never heard of jnug, but I like GDXJ for the juniors and I love small and microcap stocks, period. Gold & gold stocks are for trading, not investing, imo.
    Feb 13 09:16 AM | Likes Like |Link to Comment
  • Gold: Has The Bull Started To Run Again? [View article]
    Excellent article, thank you. I am agnostic about gold which has little inherent value. Gold is what people believe it is - money, safety, etc.
    I bought my first gold stocks in many years late Dec., 2013, sold one too early, am keeping the other one long term -- LEXVF -- unknown, unloved, a secret stock with great board chairman, the genius of mining, McKewen and a hotshot ceo. I want to buy more of it but the low volume makes it difficult.
    Feb 13 08:24 AM | Likes Like |Link to Comment
  • Why Bitcoin Matters [View article]
    Currency is whatever two parties agree it is. Great article; the future is unknowable about Bitcoin -- great fun to watch it unfold. I have never used it.
    Jan 27 09:21 AM | Likes Like |Link to Comment
  • Inovio - Sitting At The Pot Of Gold [View article]
    Misquoted; I wrote I've been trading it long since 0.51, in/out. Here is the part about Roche from the 10Q -- best place to read, not here, if one wants facts, data, and solid information, link to it at bottom:

    13. Roche Collaboration, Option and License Agreement
    In September 2013, the Company entered into a Collaborative, License, and Option Agreement (the “Agreement”) with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (“Roche”). Under the Agreement, the Company and Roche will co-develop highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B (the “Products”).
    Roche acquired an exclusive worldwide license for the Company's DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of the Company's CELLECTRA® electroporation technology for delivery of the vaccines. Roche also obtained an option to license additional vaccines in connection with a collaborative research program in prostate cancer.
    Under the terms of the Agreement, Roche made an upfront payment of $10 million and has agreed to make additional development, regulatory and commercial event based payments of up to $412.5 million. Additional event based payments could also be made to the Company if Roche pursues other indications with INO-5150 or INO-1800. Of these event based payments, we expect to achieve up to $5.0 million and $3.0 million related to INO-5150 and INO-1800, respectively, in the next two fiscal years. No event based payments or milestones were achieved during the periods presented.
    The Company is entitled to receive up to double-digit tiered royalties on product sales. Unless terminated earlier in accordance with its terms, the Agreement continues in effect until the date when no royalty or other payment obligations under the Agreement are or will become due, i.e., a royalty term ending on the later of the date that is (a) ten years after the date of the first commercial sale of the product that is subject to the Agreement or (b) the expiration of the last to expire of our patent rights that are subject to the Agreement. Under the terms of the Agreement we also agreed to perform certain research and development and manufacturing and supply services, at Roche's expense.
    The Company identified the deliverables at the inception of the agreement. The Company has determined that the license to INO-5150 and INO-1800, the Option Right to license additional vaccines, research and development services, manufacturing and drug supply, and participation in the Joint Steering Committee individually represent separate units of accounting because each deliverable has standalone value. The best estimated selling prices for these units of accounting were determined based on market conditions, the terms of comparable collaborative agreements for similar technology in the pharmaceutical and biotechnology industry, the Company's pricing practices and pricing objectives and the nature of the research and development services to be provided. While market data was considered throughout the valuation process, ultimately, the selling prices of the licenses were determined utilizing two forms of the relief from royalty method under the Income Approach and the cost-to-recreate method under the Cost Approach. The arrangement consideration was allocated to the deliverables based on the relative selling price method.
    http://1.usa.gov/LekGkI
    Jan 27 08:00 AM | 1 Like Like |Link to Comment
  • Inovio - Sitting At The Pot Of Gold [View article]
    I got those numbers from the 10Q, $3m this year, $5M next. I'm long the stock, I've been trading it long since $0.51. Often cash projections are subject to change.
    Jan 24 01:03 PM | 1 Like Like |Link to Comment
  • Inovio - Sitting At The Pot Of Gold [View article]
    You're very sensitive, Steven, I merely posed a few questions.
    Jan 24 11:08 AM | 4 Likes Like |Link to Comment
  • Inovio - Sitting At The Pot Of Gold [View article]
    As I recall there are 250m shares fully diluted. How long til possible commercial sales? More than two years going from memory but I'm not sure. I read something about flu vaccines bypassing the regular FDA schedule if proven safe, in an emergency situation. Inovio will only get $8M in milestones from Roche over the next 2 yrs, per 10Q. Will it need to raise more capital in 2015?
    Jan 24 10:25 AM | 1 Like Like |Link to Comment
  • Wellgreen Platinum: A Gem Amongst The Rubble - Genuine '10-Bagger' Upside [View article]
    I don't know what you mean; the stock has been on a tear, made a new high the other day, and its chart is lovely here. Some must love the restructuring and outlook.
    Jan 24 09:00 AM | Likes Like |Link to Comment
COMMENTS STATS
390 Comments
337 Likes